AYA ALL Care Evolves Beyond Chemotherapy as Survival Gaps Persist

Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) are living longer than ever before, but survival gaps compared with pediatric patients remain significant, according to a new review published in Blood Reviews.¹ This review explored the biologic, therapeutic, psychosocial, and socioeconomic challenges facing patients with adolescent and young adult ALL (AYA-ALL), generally defined as individuals aged 15 to 39 years.

“AYA-ALL presents an unparalleled treatment challenge due to the formative time in life when AYAs are diagnosed,” the authors wrote. They took up this investigation because AYA patients continue to experience poorer outcomes than children with ALL despite major treatment gains over the last decade. Pediatric-inspired therapeutic regimens have improved overall survival in AYA populations to greater than 70% compared with historical rates of 30% to 40% using adult-inspired regimens, but pediatric survival rates now exceed 90%.

High-Risk Biology Continues to Shape Outcomes

According to the review, the persistent survival gap is driven in part by more aggressive disease biology among AYA patients. High-risk subtypes occur more frequently in this population than in younger children, and include Philadelphia chromosome–positive (Ph+) ALL, Philadelphia-like ALL, KMT2A-rearranged ALL, and early T-cell precursor ALL. The authors also noted that central nervous system involvement is more common with age, occurring in approximately 10% of AYA patients compared with only 3% of pediatric patients.

At the same time, treatment strategies are rapidly evolving. Immunotherapies such as blinatumomab and inotuzumab ozogamicin,² as well as tyrosine kinase inhibitors for Ph+ disease, are reshaping frontline care and reducing reliance on allogeneic stem cell transplantation (alloSCT). Still, toxicity remains a major concern.

“Several studies have shown pediatric-inspired regimens still remain difficult for AYA-ALL to tolerate, leading to increased toxicities, limited doses of key drugs such as pegylated asparaginase, and lower treatment completion rates,” the review stated.¹

Ongoing clinical trials are investigating how best to incorporate immunotherapies and targeted therapies into frontline treatment while reducing chemotherapy intensity.^3-5 Researchers are also studying measurable residual disease (MRD)–guided approaches to better tailor treatment decisions. The authors emphasized that persistent MRD has become one of the strongest prognostic markers in ALL and increasingly determines whether patients should proceed to alloSCT.¹

Psychosocial and Financial Burdens Extend Beyond Treatment

Beyond disease biology, the review highlighted the profound emotional and financial strain experienced by AYA patients. Studies cited by the authors showed that 30% to 40% of AYA patients experience depression or anxiety during or after treatment. In addition, 13% meet criteria for posttraumatic stress disorder (PTSD), while nearly half report PTSD symptomatology. “Many patients also experience social isolation during treatment with a sense of disconnection from peers without similar experiences,” the authors wrote.

The review also described the economic impact of prolonged treatment, including disrupted education, delayed career development, transportation costs, lost wages, and debt accumulation. Survivors were found to have higher unemployment rates and lower earning potential than peers without cancer. Additional concerns discussed in the review included infertility, sexual health complications, obesity-related disparities, and treatment nonadherence during maintenance therapy. Studies reviewed by the authors found that nonadherence among AYA patients was associated with relapse increases ranging from 33% to 58%.⁶

These issues often go underrecognized and call for routine psychosocial screening, financial toxicity assessments, and broader multidisciplinary support for AYA patients throughout treatment and survivorship, the authors explained.¹

Expanding Access to Specialized AYA Care

The authors also found persistent disparities in access to specialized care and clinical trials. Although enrollment in clinical studies has been associated with improved outcomes for AYA patients, only about 37% participate in trials. Trial availability, insufficient staffing and resources, provider knowledge gaps, and the logistical burden placed on patients and families were cited as principal reasons.

“As the understanding of AYA-ALL disease biology and these challenges grows, it is essential for health care providers to adopt a more comprehensive approach to care that includes not only optimizing leukemia treatment through clinical trials but also through the incorporation of psychosocial care,” the authors concluded.

The findings suggest future progress in AYA-ALL may depend not only on more effective therapies but also on expanding access to specialized AYA oncology programs, survivorship clinics, fertility counseling, mental health services, and multidisciplinary care teams.

References

1. Burkart M, Dinner S. Challenges in the treatment of adolescent and young adult acute lymphoblastic leukemia: a comprehensive review. Blood Rev. Published online May 12, 2026. doi:10.1016/j.blre.2026.101397
2. Shaw ML. Inotuzumab ozogamicin outcomes in ALL validated outside of clinical trials. AJMC^®. February 4, 2026. Accessed May 22, 2026. https://www.ajmc.com/view/inotuzumab-ozogamicin-outcomes-in-all-validated-outside-of-clinical-trials
3. Blinatumomab, inotuzumab ozogamicin, and combination chemotherapy as frontline therapy in treating patients with B acute lymphoblastic leukemia. ClinicalTrials.gov. Updated May 20, 2026. Accessed May 22, 2026. https://clinicaltrials.gov/study/NCT02877303
4. Total therapy XVII for newly diagnosed patients with acute lymphoblastic leukemia and lymphoma. ClinicalTrials.gov. Updated December 5, 2025. Accessed May 22, 2026. https://clinicaltrials.gov/study/NCT03117751
5. Study of chemotherapy-free induction regimen for Ph+ acute lymphoblastic leukemia with inotuzumab ozogamicin (InO). ClinicalTrials.gov. Updated March 30, 2026. Accessed May 22, 2026. https://clinicaltrials.gov/study/NCT04747912
6. Bhatia S, Landier W, Hageman, et al. 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood. 2014;124(15):2345-2353. doi:10.1182/blood-2014-01-552166